Estrogen Pretreatment Prior to GnRH Antagonist Protocol
Phase 4
Completed
- Conditions
- Infertility
- Interventions
- Drug: 17beta-estradiol
- Registration Number
- NCT01489852
- Lead Sponsor
- Gemer
- Brief Summary
The purpose of this study is to assess whether estrogen pre-treatment can allow retrieval of 2 additional oocytes in GnRH antagonist protocol.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 472
Inclusion Criteria
- regular normo-ovulatory cycles (28 to 35 days)
- age < 38 years,
- body mass index (BMI) between 18 and 30
- first or second IVF/ICSI attempt
Exclusion Criteria
- high basal levels of serum FSH or E2,
- less than 5 follicles at the antral follicular count performed on day 3 of a spontaneous cycle,
- history of high (>20 oocytes) or low (< 5 oocytes) ovarian response in a previous IVF attempt
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Estrogen pre-treatment 17beta-estradiol -
- Primary Outcome Measures
Name Time Method number of retrieved oocytes at the ovarian puncture, 36 hours post HCG administration
- Secondary Outcome Measures
Name Time Method pregnancy rate at pregnancy test and at 6 Week US examination delivery rate 9 months later number of obtained embryos 2 days after in vitro fertilization duration of FSH administration at the end of ovarian stimulation usually after a mean of 12 days of administration number of days of administration
Total FSH dose at the end of ovarian stimulation usually after a mean of 12 days of administration daily dose x number of days of administration
Trial Locations
- Locations (1)
Service de Medecine de la Reproduction, Hôpital Jean Verdier
🇫🇷Bondy, Ile de France, France